In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Preference for erectile dysfunction treatments in patients with chronic heart failure.

Session Poster session 1 Saturday 08:30 -17:30

Speaker Ichraq nassiri

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P228

Authors : H Najih (Casablanca,MA), I Nassiri (Casablanca,MA), F Arhlade (Casablanca,MA), R Habbal (Casablanca,MA)

15 views

Authors:
H Najih1 , I Nassiri1 , F Arhlade1 , R Habbal1 , 1Ibn Rochd University Hospital, Department of Cardiology - Casablanca - Morocco ,

Citation:
European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 46

Objective: to evaluate variations in sexual and erectile function in subjects with chronic heart failure (CHF) after optimization of CHF treatment.

Methods: 160 patients men (age range 40-76 years; mean age 60 years), with CHF and erectile dysfunction (ED), were divided two groups, one under syptomatic treatment of ED; were asked all of them to complete the International Index of Erectile Function IIEF-5 before (at baseline) and 3 months after optimization of treatment of CHF.

Results: Among 160 patients studied, 47,3% have an optimal treatment of CHF versus 52,7% have not, more than 60% of patients with optimal treatment of CHF (and without symptomatic treatment of ED) showed significant improvements on the 5 domains of the IIEF-5, compared to 25% of patients without optimal treatment and under symptomatic treatment of ED (the difference was statistically significant).

Conclusion: the results of this study support that optimal treatment of CHF improves erectile function in patient with erectile dysfunction secondary to CHF better than symptomatic treatment alone.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are